AI assistant
Sending…
Aurinia Pharmaceuticals Inc. — Director's Dealing 2021
Mar 9, 2021
31941_dirs_2021-03-09_091e1a67-9881-458b-b5ad-2a4fced20e5a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-03-05
Reporting Person: MILNE GEORGE M JR (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-05 | Common Stock | P | 5000 | $13 | Acquired | 45000 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.995 to $13.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
More from Aurinia Pharmaceuticals Inc.
Regulatory Filings
2026
May 11
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
Apr 3
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3